Turkish Journal of Medical Sciences
Volume 47

Number 4

Article 30

1-1-2017

A fully liquid DTaP-IPV-HB-PRP-T hexavalent vaccine for
primaryand booster vaccination of healthy Turkish infants and
toddlers
MEHMET CEYHAN
İNCİ YILDIRIM
HASAN TEZER
İLKER DEVRİM
EMMANUEL FEROLDI

Follow this and additional works at: https://journals.tubitak.gov.tr/medical
Part of the Medical Sciences Commons

Recommended Citation
CEYHAN, MEHMET; YILDIRIM, İNCİ; TEZER, HASAN; DEVRİM, İLKER; and FEROLDI, EMMANUEL (2017) "A
fully liquid DTaP-IPV-HB-PRP-T hexavalent vaccine for primaryand booster vaccination of healthy Turkish
infants and toddlers," Turkish Journal of Medical Sciences: Vol. 47: No. 4, Article 30. https://doi.org/
10.3906/sag-1609-62
Available at: https://journals.tubitak.gov.tr/medical/vol47/iss4/30

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for
inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more
information, please contact academic.publications@tubitak.gov.tr.

Turkish Journal of Medical Sciences

Turk J Med Sci
(2017) 47: 1247-1256
© TÜBİTAK
doi:10.3906/sag-1609-62

http://journals.tubitak.gov.tr/medical/

Research Article

A fully liquid DTaP-IPV-HB-PRP-T hexavalent vaccine for primary
and booster vaccination of healthy Turkish infants and toddlers*
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Background/aim: Immunogenicity and safety of a primary series of a fully liquid, hexavalent DTaP-IPV-HB-PRP-T vaccine given at 2,
3, and 4 months of age compared to licensed comparators and a DTaP-IPV-HB-PRP-T booster at 15–18 months were evaluated.
Materials and methods: This was a Phase III, randomized, open-label trial. Primary series (no hepatitis B [HB] at birth) of DTaP-IPVHB-PRP-T (N = 155) (group 1) or licensed control vaccines (DTaP-IPV//PRP-T and standalone HB: N = 155) (group 2) and DTaP-IPVHB-PRP-T booster were administered. Noninferiority was evaluated 1 month postprimary series for anti-HB seroprotection (SP). All
other analyses were descriptive. Safety was assessed from parental reports.
Results: Postprimary series noninferiority of anti-HB ≥ 10 mIU/mL was demonstrated for the DTaP-IPV-HB-PRP-T vaccine (94.0%)
compared to the licensed control (96.1%). Postprimary series primary SP and seroconversion (SC) rates were high and similar for both
groups. Antibody persistence (prebooster) was high for each antigen and similar between groups except for HB, which was lower for
DTaP-IPV-HB-PRP-T than for standalone HB. For each antigen except HB, DTaP-IPV-HB-PRP-T booster responses were high and
similar in each group. Safety was good for primary and booster series and similar between groups.
Conclusion: The DTaP-IPV-HB-PRP-T vaccine is immunogenic and safe when administered in a challenging primary series schedule
without HB vaccination at birth.
Key words: Hexavalent, vaccine, pediatric, Turkey

1. Introduction
In recent years the improved safety of acellular pertussis
(aP) combination vaccines compared to whole cell
pertussis (wP) vaccines (1,2) together with the growing
importance of the inactivated poliovirus vaccine (IPV)
compared to the oral poliovirus vaccine (OPV) in the
context of the polio eradication endgame (3) has driven
the need for their wider availability. In this context, Sanofi
Pasteur has built on the wide experience with Pentaxim/
Pentavac, an established pediatric pentavalent diphtheria
(D), tetanus (T), aP, IPV, and Hemophilus influenzae
type b (PRP-T) vaccine (4), to develop a fully liquid,
hexavalent DTaP-IPV-hepatitis B (HB)-PRP-T vaccine
(Hexaxim/Hexyon/Hexacima) that has the same D, T,
aP, IPV, and PRP-T composition as Pentaxim/Pentavac.
Additionally, the hexavalent vaccine incorporates a HB

antigen of proven immunogenicity and safety (5–8). Such
combination vaccines are increasingly pivotal to national
immunization schedules globally and are increasingly
important in addressing regional disparities in vaccination
coverage and composition (4,9).
In previous studies, the investigational DTaP-IPVHB-PRP-T vaccine has been shown to be safe and
immunogenic when administered in a 3-dose primary
series schedule at 2, 4, and 6 months (7) and 6, 10, and
14 weeks (10), with or without the administration of a
standalone HB vaccine at birth (10–13). Additionally, a
booster dose in the second year of life has been shown to
be safe and to elicit an anamnestic response irrespective of
HB vaccination at birth (11,14).
As part of an extensive clinical development plan
conducted largely outside Europe (Central America

* Data presented at the 5th Asian Congress of Pediatric Infectious Diseases, 23–26 September 2010, Taipei, Taiwan
** Correspondence: emmanuel.feroldi@sanofipasteur.com
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(11), South America (8,13,15,16), Thailand (12), and
South Africa (10, 14), and prior to the approval of this
vaccine by the European Medicines Agency in 2013 via
the Centralised Procedure (17), the present study was
performed in Turkey to evaluate the performance of the
vaccine when used with a 2, 3, 4 month infant primary
series versus control vaccines (without a HB vaccination
at birth) and also to assess the immunogenicity before and
after a toddler booster dose of the investigational vaccine
in the second year of life. This corresponded to the infant
DTaP vaccination schedule in use in Turkey at the time of
the study. The 2, 3, 4 month schedule, with only 1 month
between vaccinations, is more challenging than the more
widely studied 2, 4, 6 month primary series schedule in
terms of generating strong and lasting immune responses
against HB, especially in the absence of a birth dose
of a standalone HB vaccine. However, previous results
following administration of DTaP-IPV-HB-PRP-T in
the even more challenging 6, 10, 14 week schedule in
South African infants with or without HB vaccination at
birth were encouraging (10,14), and in order for a new
combination vaccine to have global implications, a wide
range of vaccination schedules needs to be evaluated.
2. Materials and methods
2.1. Study design and participants
Two consecutive Phase III studies were carried out at a
single center in Turkey (Hacettepe University Medical
Faculty, Ankara, Turkey): the first, infant primary series
vaccination study, was randomized, active-controlled, and
open-label (ClinicalTrials.gov: NCT00315055), and in the
second study all toddler participants received the same
booster vaccination (ClinicalTrials.gov: NCT00619502).
The study site’s independent ethics committee approved
the study protocols and amendments. Both studies
conformed to Good Clinical Practice, applicable
International Conference on Harmonization guidelines,
the ethical principles of the Declaration of Helsinki
(Edinburgh revision, October 2000), and the European
Directive 2001/20/EC, and were conducted in accordance
with local regulations. Prior to enrolment, at least one
parent or legally acceptable representative (and witness for
the booster study only), as well as the study investigator,
signed an informed consent form. The primary and
booster studies took place between June 2006 and June
2007 and December 2007 and July 2008, respectively.
Healthy infants aged 2 months, born at full term (≥37
weeks), and with birth weight ≥2.5 kg were eligible for the
primary series study. The main exclusion criteria were:
recent (in the 4 weeks prior to the first vaccination) or
planned participation in another clinical trial or nonstudy
vaccination during or in the 4 weeks prior to the study
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period (except Bacillus Calmette-Guerin vaccination) or
any planned nonstudy vaccination in the 4 weeks after
each vaccination; any prior vaccination against diphtheria,
tetanus, pertussis, poliomyelitis, HB, Hemophilus
influenzae type b (Hib) diseases, or any history of these
infections; receipt of blood products since birth or
history of any immune-modifying treatment; personal/
maternal history of immunodeficiency, including human
immunodeficiency virus, HB surface antigen (HBsAg),
or hepatitis C positivity; known systemic hypersensitivity
to any vaccine component; history of seizures; bleeding
disorder contraindicating intramuscular (IM) injection;
chronic illness that could interfere with study conduct/
completion; or febrile (axillary temperature ≥37.4 °C
[rectal equivalent ≥38.0 °C]) at enrolment. Children were
excluded from the booster study if they had, additionally:
previous booster vaccination against diphtheria, tetanus,
pertussis, poliomyelitis, HB, or Hib; any vaccine-related
serious adverse event (SAE) that occurred during the
primary study; any known contraindication to further
vaccination with a pertussis vaccination.
Participants were randomized equally in the primary
study to receive the investigational DTaP-IPV-HB-PRP-T
vaccine (Hexaxim/Hexyon/Hexacima) (group 1) or
control vaccines, DTaP-IPV//PRP-T (Pentaxim/Pentavac)
co-administered with a standalone HB vaccine (Engerix B)
(group 2), at 2, 3, and 4 months of age. A permuted block
randomization method was used to guarantee similar
number of participants in each group at any time. All
participants in the booster study received a single dose
of DTaP-IPV-HB-PRP-T at 15–18 months of age. In the
primary study, vaccines were administered into the right
thigh (DTaP-IPV-HB-PRP-T or DTaP-IPV//PRP-T) and
left thigh (HB [group 2 only]), and in the booster study
DTaP-IPV-HB-PRP-T was administered into the right
deltoid muscle.
2.2. Vaccines
The investigational hexavalent vaccine (batch numbers
PFAGI00701B [infant primary series study] and S4009
[toddler booster study]) was manufactured by Sanofi
Pasteur, France, and supplied as a fully liquid suspension
for injection in single dose (0.5 mL) prefilled syringes.
Each prefilled syringe contained ≥20 IU (30 limit of
flocculation [Lf]) D-toxoid; ≥40 IU (10 Lf) T-toxoid; 25 µg
PT; 25 µg FHA; 40, 8, and 32 D antigen units of poliovirus
type 1, 2, and 3, respectively; 10 µg HBsAg; 12 µg Hib
polysaccharide conjugated to 22–36 µg tetanus protein
(PRP-T); and 0.6 mg aluminum hydroxide.
The control pentavalent vaccine was supplied by Sanofi
Pasteur as a separate DTaP-IPV suspension (batch number
Z0165) and freeze-dried PRP-T (batch number Y0660),
which were reconstituted to provide a 0.5 mL dose prior

CEYHAN et al. / Turk J Med Sci
to vaccination. The pentavalent vaccine had the same D,
T, aP, IPV, and PRP-T composition as the investigational
vaccine. The HB standalone vaccine was manufactured
by GlaxoSmithKline (commercial batch) and presented
as a 0.5 mL dose containing 10 µg purified recombinant
HBsAg in a prefilled syringe.
2.3. Serology
Blood samples were collected prior to the first
vaccination (3 mL), 1 month after the third vaccination
(5 mL: postprimary series response), prior to the booster
vaccination (5 mL: antibody persistence), and 1 month
after the booster vaccination (5 mL: booster response)
for immunogenicity assessment of the investigational and
control vaccines.
All assays were performed either at the Sponsor’s
Global Clinical Immunology (GCI) laboratory in the USA
or at qualified contract laboratories approved by GCI.
Antidiphtheria antibody concentrations (IU/mL) and
antipolio 1, 2, 3 antibody titers (1/dil) were assayed by a
neutralization assay (with an assay against Mahoney, MEF1, and Saukett poliovirus strains), antitetanus (IU/mL),
anti-FHA (EU/mL), anti-PT (EU/mL) concentrations by
an enzyme linked immunosorbent assay (ELISA), antiPRP-T (µg/mL) concentrations by a radioimmunoassay,
and anti-HB concentrations (mIU/mL) by a commercially
available chemiluminescence assay (VITROS ECi/ECiQ).
2.4. Reactogenicity and safety
Participants were monitored for immediate unsolicited
adverse events (AEs) for 30 min after each vaccination.
For 7 days after each vaccination, parent(s)/legal
representative(s) used diary cards to record the duration and
intensity (see Tables 4 and 5 for definitions of intensity)1 of
predefined (solicited) injection site (tenderness, erythema,
swelling [recorded separately for DTaP-IPV//PRP-T and
HB vaccination sites in group 2], and extensive swelling
of the vaccinated limb2) and systemic (fever, vomiting,
abnormal crying, drowsiness, appetite lost, irritability)
reactions (also considered by definition to be related to the
vaccination). For temperature measurement the axillary
route was used for cultural and compliance reasons.
Unsolicited AEs were recorded using diary cards for
30 days after each vaccination: unsolicited injection site
AEs were considered to be related to the vaccination and
for unsolicited systemic AEs the Investigator assessed the
relationship to the vaccination. Serious adverse events
were collected throughout until 6 months after the last
primary series or the booster vaccination. The Investigator
assessed their relationship to the vaccination.
1

2

2.5. Statistical analyses
The primary statistical objective of the primary series
study was to demonstrate noninferiority of the anti-HB
response, based on the seroprotection threshold of 10
mIU/mL, of the investigational vaccine compared to
the control vaccines 1 month postprimary series. The
secondary objective of the primary series study was to
describe the immune response for each antigen at 1 month
postprimary series, and for the booster study objectives
were to describe the prebooster (antibody persistence),
and 1 month postbooster response. Safety was evaluated
throughout the two studies.
Seroprotection rates (D, T, IPV, HB, PRP-T),
seroconversion rates (PT, FHA), geometric mean titers
(GMTs, for IPV), and geometric mean concentrations
(GMCs, for D, T, PT, FHA, HB, PRP-T) with their
associated 95% confidence intervals (CIs) were used to
describe the immune responses, and are presented in
Table 1. The 95% CIs were calculated using the normal
approximation method for GMCs and GMTs and using the
exact binomial distribution (Clopper–Pearson method)
for percentages (18).
The noninferiority analysis for the primary objective
(comparison of the HB component of the investigational
vaccine to the standalone HB vaccine administered with
Pentaxim/Pentavac) was carried out using the per protocol
(PP) analysis set (and confirmed using the Full Analysis
Set [FAS]) based on the lower bound of the two-sided
95% CI of the difference in anti-HB seroprotection rates
(≥10 mIU/mL) (group 1–group 2), with noninferiority
being concluded if the lower bound of this 95% CI was
>–10% (the clinical delta). The 95% CI was calculated using
the Wilson score method without continuity correction as
quoted by Newcombe (19).
Safety was described by vaccine group after each and
any vaccine administration. For each safety criterion
(symptom) the percentage of participants with the given
symptom was calculated with its 95% CI.
The sample size calculation was based on the
noninferiority test for the primary objective, with a
planned sample size of 310 participants (155 participants in
each group) to allow 258 evaluable participants (assuming
an attrition rate of approximately 15%). The sample size
was calculated using the Farrington and Manning formula
(20), with an alpha level of 2.5% (one-sided hypothesis)
and to obtain an overall power of 90%.
Data from the PP population (participants with no
protocol violation that could have interfered with the

Not applicable for extensive swelling of the vaccinated limb, which was only recorded for the booster vaccination, and for which the
circumference of the injected limb was to have been measured and recorded in the diary card and any such occurrence was to be considered Grade 3 by convention.
Extensive swelling of the vaccinated limb was only assessed after the booster vaccination.
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primary evaluation criteria, and analyzed according to the
vaccine received) were presented for all immunogenicity
assessments. The safety evaluation used the safety analysis
set (SafAS) (participants who received at least one primary
vaccination and all who received the booster, and analyzed
according to the primary series vaccine received). Data
from the FAS (those who received at least one vaccination,
and analyzed according to the randomization) supported
the evaluation done using the PP population.
The statistical analyses were done using SAS software
Version 8.2 for the primary series study and Version 9.1 for
the booster study (SAS Institute, Cary, NC, USA).
3. Results
3.1. Participants studied
In total, 310 participants were enrolled for primary infant
vaccination, with 155 randomized to each group. All
received at least one dose of vaccine and 152 and 150
participants in groups 1 and 2, respectively, completed the
primary infant series in accordance with the protocol. Of
these, 130 and 124 returned for the booster vaccination;
all 254 were assessed for antibody persistence prior to
the DTaP-IPV-HB-PRP-T booster vaccination, with 122
and 114 completing the booster phase in groups 1 and 2,
respectively. Demographic characteristics were similar in
each group, and participant disposition is summarized in
Figure 1.
3.2. Immunogenicity
For the anti-HB response 1 month after the primary
vaccination series, the seroprotection rate (≥10 mIU/mL)
with its 95% CI was 94.0 (88.6; 97.4) in group 1 and 96.1
(91.1; 98.7) in group 2 (Table 1). The statistical difference
(group 1–group 2) was –2.06 (–7.83; 3.65), thereby
confirming noninferiority of group 1 to group 2, as the
lower 95% CI for the difference was >–10% (Table 1).
The full immunogenicity data for each antigen,
threshold, and including the GMCs and GMTs for
postprimary, prebooster, and postbooster are presented
in Table 2. No statistical comparisons were performed for
these data. For the evaluation at 1 month postprimary series,
the seroprotection rates were similar in both groups for all
antigens. Prior to the booster, the majority of participants
remained seroprotected against HB (≥10 mIU/L), PRP-T
(≥0.15 µg/mL), D (≥0.01 IU/mL), T (≥0.01 IU/mL),
polio (≥8 [1/dil]), and GMCs for anti-PT and anti-FHA
were similar in each group. However, it is noted that the
prebooster anti-HB ≥10 mIU/mL was significantly lower
(based on nonoverlapping CIs) for group 1 (80.7% [GMC
44.2 mIU/mL)]) than for group 2 (99.0% [GMC 223 mIU/
mL]). One month postbooster vaccination, the anti-HB
seroprotection was similar in each group for both the 10
mIU/mL threshold (97.3% and 98.6%) and the 100 mIU/
mL threshold (86.5% and 93.0%), although the GMCs
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were significantly lower (based on nonoverlapping 95%
CIs) for group 1 (1379 mIU/mL) than for group 2 (26189
mIU/mL). For the remaining valences, strong postbooster
increases in antibody GMCs and GMTs were observed,
resulting in high seroprotection (PRP-T, D, T, polio 1, 2,
3) and seroconversion (PT and FHA) rates, which were
similar in each group.
The anti-HB booster response was further investigated
in a post hoc analysis by assessing the response in those
participants with a prebooster anti-HB concentration <10
mIU/mL and those ≥10 mIU/mL (Table 3). It should be
noted that this analysis was based on a small sample size
and is descriptive. This analysis showed that the postbooster
response at the 10 mIU/mL threshold was similar for both
subgroups (100% and 95.0% of participants ≥10 mIU/
mL postbooster, for a prebooster anti-HB concentration
of ≥10 mIU/mL and <10 mIU/mL, respectively), i.e. was
independent of the prebooster anti-HB concentration.
However, at the 100 mIU/mL threshold and in terms of
GMC the response was higher in participants who had
prebooster anti-HB levels ≥10 mIU/mL (79.9% and 50.0%
of participants ≥100 mIU/mL postbooster, for a prebooster
anti-HB concentration of ≥10 mIU/mL and <10 mIU/mL,
respectively, with corresponding GMCs of 2745 mIU/mL
and 135 mIU/mL).
3.3. Safety and tolerability
No immediate AEs were reported, and the solicited
injection site and systemic reactions for both the primary
series and booster vaccination are summarized in Table 4
(injection site) and Table 5 (systemic).
For the primary series, the overall incidence of solicited
reactions was similar for the two vaccine groups and most
were Grade 1 or 2. In each group, tenderness was the
most common solicited injection site reaction (62.1% and
53.9% of participants for the DTaP-IPV-HB-PRP-T and
DTaP-IPV//PRP-T vaccines, respectively) and irritability
was the most common solicited systemic reaction (68.0%
and 65.1% of participants for the DTaP-IPV-HB-PRP-T
and DTaP-IPV//PRP-T vaccines, respectively). Overall,
the incidence of fever was slightly higher in group 1
(41.2% and 28.3% of participants for the DTaP-IPV-HBPRP-T and DTaP-IPV//PRP-T vaccines, respectively), but
episodes classified as Grade 3 were similar in incidence
in each group 2.0% of participants in each group); for
all other solicited reactions the incidence was similar
in each group both overall and for Grade 3. Unsolicited
AEs within 7 days after any primary series vaccination
were similar in each group (3.3% versus 5.9% in groups
1 and 2, respectively), with none in group 1 and a single
episode of diarrhea in group 2 considered related to the
vaccination. In both groups, unsolicited AEs occurring
within 30 days of vaccine injection were reported by
<19% of participants. There were no withdrawals due
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Participants randomized/injected
N=310

GROUP 1

GROUP 2

DTaP-IPV-Hep B-PRP-T primary series
2, 3, 4 months of age
Full analysis set: N=155

DTaP-IPV//PRP~T and hepatitis B primary series
2, 3, 4 months of age
Full analysis set: N=155

Excluded from per protocol analysis set: N=14*

Excluded from per protocol analysis set: N=10*
Inclusion criterion not met: 3
Not received 3 injections: 3
No postprimary series blood sample: 3
Nonstudy vaccination: 1
Unacceptable time interval between vaccinations 1 and 2: 2
Unacceptable time interval between vaccinations 2 and 3: 3

Inclusion criterion not met: 4
Not received 3 injections: 5
No postprimary series blood sample: 5
Nonstudy vaccination: 3
Unacceptable time interval between vaccinations 1 and 2: 4
Unacceptable time interval between vaccinations 2 and 3: 1
Unacceptable time interval between vaccination 3 and blood sample: 3

Completed primary series:152
Completed primary series (PP analysis set): N=145

Completed primary series: N=150
Completed primary series (PP analysis set): N=141

Completed 6-month
follow-up
Full analysis set: N=136

Completed 6-month
follow-up
Full analysis set: N=141

Assessed for antibody persistence prebooster
Full analysis set: N=130

Assessed for antibody persistence prebooster
Full analysis set: N=124

DTaP-IPV-Hep B-PRP-T booster
15-18 months of age
Full analysis set: N=254

Lost to followup during booster phase: N=8

Lost to followup during booster phase: N=10

Completed booster phase: N=122

Completed booster phase: N=114

Completed 6-month follow-up: N=109

Completed 6-month follow-up: N=106

Figure 1. Disposition of study participants.
*Note that participants could have more than one reason for exclusion from the PP analysis set.

to an AE and the overall incidence of SAEs was 1.3% (2
participants) in group 1 (bronchopneumonia and upper
respiratory tract infection) and 2.0% (3 participants) in
group 2 (bronchiolitis, bronchopneumonia, and road

traffic accident); no SAE was considered to be related to
vaccination, all occurred before the 6-month follow-up
period, and there were no deaths.
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Table 1. Noninferiority analysis for the primary objective (anti-HB response postprimary series) (PP analysis set).
Group 1

Anti-HB ≥10
mIU/mL

Group 2

Group 1 minus Group 2

n/M

95% CI

n/M

95% CI

%
observed

2-sided
95%CI

Clinical
deltaa

Conclusion

126/134
(94%)

(88.6; 97.4)

123/128
(96.1%)

(91.1; 98.7)

–2.06

(–7.88; 3.65)

10

Noninferiority

n = number of participants
M = number of participants with evaluable data
Group 1= DTaP-IPV-HB-PRP-T primary series and DTaP-IPV-HB-PRP-T booster
Group 2 = DTaP-IPV//PRP-T + HB primary series and DTaP-IPV-HB-PRP-T booster
a
Noninferiority to be concluded if lower bound of the 95% CI greater than –10
Table 2. Seroprotection rates, seroconversion rates, geometric mean concentrations, and titers 1 month postdose 3 (2, 3, 4 months of
age), prebooster, and 1 month postbooster (PP analysis set).
Antibody

Anti-HB

Anti-PRP-T

Anti-D

Anti-T

Antipolio type 1

Antipolio type 2

Antipolio type 3

Anti-PT

Anti-FHA

Criteria

Group 1

Group 2

Postprimary

Prebooster

Postbooster

Postprimary

Prebooster

Postbooster

≥10 mIU/mL

94.0 (88.6; 97.4)

80.7 (72.1; 87.7)

97.3 (92.3; 99.4)

96.1 (91.1; 98.7)

99.0 (94.7; 100.0)

98.6 (96.0; 97.7)

≥100 mIU/mL

64.9 (56.2; 73.0)

33.9 (25.1; 43.6)

86.5 (78.7; 92.2)

78.1 (70.0; 84.9)

76.7 (67.3; 84.5)

93.0 (88.7; 96.0)

GMC (mIU/mL) 149 (115; 191)

44.2 (32.3; 60.7)

1379 (916; 2078)

265 (205; 342)

223 (176; 282)

26189 (19133; 35846)

≥0.15 µg/mL

90.7 (84.6; 95.0)

85.0 (77.0; 91.0)

100.0 (96.8; 100.0)

97.8 (93.8; 99.5)

83.3 (74.7; 90.0)

100.0 (96.5; 100.0)

≥1 µg/mL

72.9 (64.7; 80.0)

41.6 (32.4; 51.2)

98.2 (93.8; 99.8)

76.8 (68.9; 83.6)

33.3 (24.3; 43.4)

100.0 (96.5; 100.0)

GMC (µg/mL)

2.12 (1.62; 2.77)

0.724 (0.541; 0.968)

72.5 (55.8; 94.3)

2.37 (1.91; 2.94)

0.612 (0.443; 0.844) 86.9 (69.8; 108)

>0.01 IU/mL

99.3 (96.2; 100.0)

90.4 (83.0; 95.3)

100.0 (96.8; 100.0)

97.1 (92.7; 99.2)

88.3 (80.0; 94.0)

100.0 (96.3; 100.0)

>0.1 IU/mL

34.0 (26.3; 42.4)

12.5 (6.8; 20.4)

99.1 (95.1; 100.0)

44.2 (35.8; 52.9)

14.9 (8.4; 23.7)

100.0 (96.3; 100.0)

>1.0 IU/mL

0.0 (0.0; 2.5)

NC

90.2 (83.1; 95.0)

0.7 (0.0; 4.0)

NC

95.9 (89.9; 98.9)

GMC (IU/mL)

0.071 (0.060; 0.084)

0.028 (0.022; 0.035)

5.09 (3.89; 6.66)

0.091 (0.075; 0.110)

0.032 (0.024; 0.041) 10.2 (7.59; 13.8)

>0.01 IU/mL

100.0 (97.5; 100.0)

100.0 (96.3; 100.0)

100.0 (96.7; 100.0)

100.0 (97.4; 100.00)

100.0 (96.0; 100.0)

100.0 (96.2; 100.0)

>0.1 IU/mL

100.0 (97.5; 100.0)

83.5 (74.6; 90.3)

100.0 (96.7; 100.0)

98.6 (94.9; 99.8)

77.8 (67.8; 85.9)

100.0 (96.2; 100.0)

>1.0 IU/mL

43.4 (35.2; 51.9)

NC

98.2 (93.5; 99.8)

32.4 (24.7; 40.8)

NC

99.0 (96.5; 99.9)

GMC (IU/mL)

0.839 (0.731; 0.962)

0.244 (0.204; 0.292)

8.98 (7.52; 10.7)

0.709 (0.625; 0.804)

0.194 (0.158; 0.238) 13.1 (10.8; 15.8)

≥8 (1/dil)

97.7 (91.9; 99.7)

98.9 (93.8; 100.0)

100.0 (96.5; 100.0)

97.9 (92.5; 99.7)

98.8 (93.7; 100.0)

100.0 (95.8; 100.0)

GMT ([1/dil])

102 (74.9; 138)

110 (81.6; 148)

5477 (4401; 6814)

112 (85.4; 147)

114 (82.4; 157)

9050 (7134; 11480)

≥8 (1/dil)

94.7 (86.9; 98.5)

100.0 (95.7; 100.0)

100.0 (96.4; 100.0)

94.0 (86.5; 98.0)

97.7 (91.9; 99.7)

100.0 (95.7; 100.0)

GMT ([1/dil])

73.5 (52.9; 102)

114 (84.9; 153)

6099 (4916; 7566)

78.2 (58.2; 105)

131 (95.3; 179)

9170 (7170; 11727)

≥8 (1/dil)

97.4 (90.8; 99.7)

85.2 (76.1; 91.9)

100.0 (96.4; 100.0)

100.0 (95.4; 100.0)

96.3 (90.1; 99.3)

100.0 (98.0; 100.0)

GMT ([1/dil])

133 (93.0; 190)

47.1 (33.1; 67.1)

5542 (4156; 7392)

214 (159; 288)

101 (73.0; 141)

10152 (7806; 13205)

≥4-fold rise

93.6 (88.2; 97.0)

NA

96.5 (90.1; 99.3)

94.2 (89.0; 97.5)

NA

96.2 (89.3; 99.2)b

GMC (EU/mL)

123 (109; 139)

6.08 (4.74; 7.79)

160 (137; 187)

138 (122; 155)

7.49 (597; 9.41)

237 (202; 278)

≥4-fold rise

81.9 (74.7; 87.9)

NA

91.8 (83.0; 96.9)

83.1 (75.7; 89.0)

NA

97.4 (90.9; 99.7)

GMC (EU/mL)

102 (90.4; 114)

12.5 (9.59; 16.4)

222 (194; 254)

69.3 (62.0; 77.6)

8.18 (6.49; 10.3)

234 (201; 272)

a

a

b

a

a

Data are % (95% CI) participants with titer or concentration above threshold, GMC or GMT
Group 1 = DTaP-IPV-HB-PRP-T primary series and DTaP-IPV-HB-PRP-T booster
Group 2 = DTaP-IPV//PRP-T + HB primary series and DTaP-IPV-HB-PRP-T booster
a
increase from preprimary series; bincrease from prebooster; PP = per protocol; D = diphtheria; T = tetanus; PT = pertussis toxin; FHA = filamentous hemagglutinin; HB =
hepatitis B; PRP-T = Hemophilus influenzae type b; NC = not calculated; NA = not applicable
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Table 3. Postbooster antihepatitis B response in group 1 participants with a HB concentration < 10 mIU/L or ≥10 mIU/mL prebooster
(PP analysis set).
Group 1
Antibody

Anti-HB (mIU/mL)

Criteria

Participants with prebooster
<10 mIU/mL (N = 21)

Participants with prebooster
≥10 mIU/mL (N = 88)

≥10

95.0 (75.1; 99.9)

100 (95.9; 100)

≥100

50.0 (27.2; 72.8)

97.7 (92.0; 99.7)

GMC prebooster (IU/mL)

3.72 (2.91; 4.75)

79.9 (61.4; 104)

GMC postbooster (IU/mL)

135 (56.9; 320)

2745 (1938; 3886)

Data are % (95% CI) participants fulfilling the given criteria or GMC
Group 1 = DTaP-IPV-HB-PRP-T primary series and DTaP-IPV-HB-PRP-T booster
PP = per protocol; HB = hepatitis B; GMC = geometric mean concentration
Table 4. Percentage of participants experiencing solicited injection site reactions occurring in the 7 days after any dose of any vaccine
(SafAS).
Primary series vaccination
Group 2

Any injection
site reaction
Tenderness
Redness
Swelling

Booster vaccination

Gradea

Group 1
(N = 153)

DTaP-IPV//PRP-T
(N = 152)

Engerix B
(N = 152)

Group 1
(N = 130)

Group 2
(N = 122)

Any

69.9 (62.0; 77.1)

NC

NC

50.4 (41.2; 59.6)

65.8 (56.2; 74.5)

Grade 3

13.7 (8.7; 20.2)

NC

NC

5.0 (1.8; 10.5)

7.2 (3.2; 13.7)

Any

62.1 (53.9; 69.8)

53.9 (45.7; 62.1)

49.3 (41.1; 57.6)

46.3 (37.2; 55.6)

60.4 (50.6; 69.5)

Grade 3

11.8 (7.1; 18.0)

7.9 (4.1; 13.4)

9.2 (5.1; 15.0)

3.3 (0.9; 8.2)

1.8 (0.2; 6.4)

Any

34.0 (26.5; 42.1)

25.0 (18.3; 32.7)

15.8 (10.4; 22.6)

28.9 (21.0; 37.9)

45.0 (35.6; 54.8)

Grade 3

0.7 (0.0; 3.6)

0.0 (0.0; 2.4)

0.7 (0.0; 3.6)

2.5 (0.5; 7.1)

3.6 (1.0; 9.0)

Any

23.5 (17.1; 3.6)

20.4 (14.3; 27.7)

17.1 (11.5; 24.0)

21.5 (14.5; 29.9)

32.4 (23.9; 42.0)

Grade 3

2.6 (0.7; 6.6)

0.0 (0.0; 2.4)

0.0 (0.0; 2.4)

1.7 (0.2; 5.8)

2.7 (0.6; 7.7)

Data are % of participants (95% CI)
SaFAS = safety analysis set; NC = not calculated
Group 1 = DTaP-IPV-HB-PRP-T primary series and DTaP-IPV-HB-PRP-T booster
Group 2 = DTaP-IPV//PRP-T + HB primary series and DTaP-IPV-HB-PRP-T booster
a
Grade 1, 2, and 3 pain were defined as ‘minor reaction when injection site is touched’, ‘cries or protests when injection site is touched’,
and ‘cries when injected limb is moved or the movement of the injected limb is reduced’. For erythema and swelling, a diameter of <2.5
cm was assessed as Grade 1, from 2.5 to <5 cm as Grade 2, and ≥5 cm as Grade 3

For the DTaP-IPV-HB-PRP-T booster vaccination, the
incidence of solicited injection site and systemic reactions
was similar for the two primary series vaccine groups, and
most were classified as Grade 1 or 2. In particular, there
were no episodes of extensive swelling of the vaccinated
limb (and so this solicited reaction for the booster phase is
not presented in Table 3). The incidence of unsolicited AEs

within 7 days of the booster vaccination was low (9.1% and
9.9% of participants in groups 1 and 2, respectively, with
the most commonly reported being upper respiratory tract
infection in group 1 [3.3%] and nasopharyngitis in group
2 [4.5%]); two participants in group 1 (1.7% [injection
site hemorrhage]) and none in group 2 reported an AE
considered to be related to the vaccination. In the 30 days
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Table 5. Percentage of participants experiencing solicited systemic reactions occurring in the 7 days after any dose of any vaccine
(SafAS).

Any systemic reaction
Fever
Vomiting
Abnormal crying
Drowsiness
Appetite lost
Irritability

Primary series vaccination

Booster vaccination

Gradea

Group 1
(N = 153)

Group 2
(N = 152)

Group 1
(N = 130)

Group 2
(N = 122)

Any

81.7 (74.6; 87.5)

76.3 (68.7; 82.8)

50.4 (41.2; 59.6)

65.8 (56.2; 74.5)

Grade 3

36.6 (29.0; 44.8)

24.3 (17.8; 32.0)

12.4 (7.1; 19.6)

12.6 (7.1; 20.3)

Any

41.2 (33.3; 49.4)

28.3 (21.3; 36.2)

24.0 (16.7; 32.6)

32.4 (23.9; 42.0)

Grade 3

2.0 (0.4; 5.6)

2.0 (0.4; 5.7)

0.8 (0.0; 4.5)

0.0 (0.0; 3.3)

Any

50.3 (42.1; 58.5)

45.4 (37.3; 53.7)

10.7 (5.8; 17.7)

9.9 (5.1; 17.0)

Grade 3

17.6 (12.0; 24.6)

12.5 (7.7; 18.8)

1.7 (0.2; 5.8)

1.8 (0.2; 6.4)

Any

55.6 (47.3; 63.6)

40.8 (32.9; 49.0)

24.0 (16.7; 32.6)

31.5 (23.0; 41.0)

Grade 3

17.0 (11.4; 23.9)

10.5 (6.1; 16.5)

2.5 (0.5; 7.1)

3.6 (1.0; 9.0)

Any

44.4 (36.4; 52.7)

46.7 (38.6; 55.0)

19.8 (13.1; 28.1)

22.5 (15.1; 13.4)

Grade 3

4.6 (1.9; 9.2)

7.2 (3.7; 12.6)

1.7 (0.2; 5.8)

2.7 (0.6; 7.7)

Any

47.7 (39.6; 55.9)

46.7 (38.6; 55.0)

33.1 (24.8; 42.2)

38.7 (29.6; 48.5)

Grade 3

10.5 (6.1; 16.4)

7.9 (4.1; 13.4)

7.4 (3.5; 13.7)

7.2 (3.2; 13.7)

Any

68.0 (60.5; 75.3)

65.1 (57.0; 72.7)

42.1 (33.2; 51.5)

55.0 (45.2; 64.4)

Grade 3

20.3 (14.2; 27.5)

14.5 (9.3; 21.1)

4.1 (1.4; 9.4)

6.3 (2.6; 12.6)

Data are % of participants (95% CI)
SaFAS = safety analysis set
Group 1 = DTaP-IPV-HB-PRP-T primary series and DTaP-IPV-HB-PRP-T booster
Group 2 = DTaP-IPV//PRP-T + HB primary series and DTaP-IPV-HB-PRP-T booster
Grade 1, 2, and 3 fever were defined as temperature (axillary equivalent) ≥37.4 °C–≤37.9 °C, >38.0 °C–≤38.9 °C, and >39.9 °C,
respectively. Other systemic symptoms were defined as: vomiting (Grade 1, 1 episode/day; Grade 2, 2 to 5 episodes/day; Grade 3, ≥6
episodes /day or requiring parenteral hydration), abnormal crying (Grade 1, <1 h; Grade 2, 1–3 h; Grade 3, >3 h), drowsiness (Grade
1, unusually sleepy; Grade 2, not interested in surroundings or did not wake up for a meal; Grade 3, sleepy most of the time or difficult
to wake up), appetite lost (Grade 1, eating less than normal; Grade 2, missed 1 to 2 meals; Grade 3, missed ≥3 meals), and irritability
(Grade 1, easily consolable; Grade 2, requiring increased attention; Grade 3, inconsolable)

postbooster, 15.7% and 18.0% of participants in groups 1
and 2, respectively, reported an unsolicited AE: there were
no SAEs during this time. During the 6-month follow-up
period 6 participants (2.4%) reported an SAE, none of
which were considered to be related to vaccination. There
were no deaths or withdrawals due to an AE during the
booster phase.
4. Discussion
With the exception of the HB antigen, all antigens
included in the fully liquid hexavalent vaccine have
been extensively studied both as part of the pentavalent
vaccine (Pentaxim/Pentavac) (4) and also in a clinical
trial designed specifically to assess the noninferiority of
all antigens to Pentaxim/Pentavac and a standalone HB
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vaccine (13). This previous study showed noninferiority of
immune responses for all antigens, including HB (with no
HB vaccination at birth). Compared to the present study,
the HB response has been higher postprimary vaccination
series for the less challenging 2, 4, 6 month schedule (13)
or postbooster when a HB dose had been administered
at birth (14). However, the differences in study design in
terms of vaccination schedule and the administration of a
birth dose of HB compound comparisons between studies
and more importantly numerous studies have consistently
shown noninferiority of immune responses against HB to
both standalone HB vaccine and to HB antigens included
in multivalent comparator vaccines, in a range of schedules,
both with and without HB vaccination at birth. These
studies have been published separately and reviewed (5).
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The present study, therefore, was not powered to assess
all antigens statistically, since such comparisons have been
done previously in appropriately powered studies both for
the investigational DTaP-IPV-HB-PRP-T vaccine (5–7)
and for the D, T, aP, IPV, and PRP-T antigens that are the
same as those contained in the established control DTaPIPV//PRP-T vaccine (4); instead, the present study was
designed to assess the noninferiority of only the HB antigen
compared to a standalone HB vaccine (administered with
Pentaxim/Pentavac) at 1 month after a 3-dose primary
series in terms of SP rate. The response to the remaining
antigens is presented descriptively. As expected from other
studies, noninferiority was demonstrated for HB after the
primary vaccination series, and the responses for all other
antigens were strong and similar between the two groups.
In this study a DTaP-IPV-HB-PRP-T booster was
administered to both primary vaccination groups (i.e.
the same booster for participants who had received
either DTaP-IPV-HB-PRP-T or Pentaxim/Pentavac and
a standalone HB as the primary series) to establish the
suitability of DTaP-IPV-HB-PRP-T given as a booster
in either scenario. The anti-HB antibody persistence
prebooster was lower for DTaP-IPV-HB-PRP-T than for
the standalone HB vaccine (SP rate ≥10 mIU/mL [GMC]
of 80.7% [44.2 mIU/mL] and 99.0% [223 mIU/mL] for
groups 1 and 2, respectively). However, as has been seen
with other challenging vaccination schedules (14), the
anti-HB seroprotection rate (10 mIU/mL threshold) after a
booster dose of the hexavalent vaccine is similar even when
comparing groups with different prebooster seroprotection
rates (97.3% and 98.6% for groups 1 and 2, respectively).
In terms of SP ≥10 mIU/mL and GMC, however, the
postbooster response was lower for DTaP-IPV-HB-PRP-T
(86.5% and 44.2 mIU/mL) than for the standalone HB
vaccine (93.0 and 223 mIU/mL), although this should be
considered in the context of the high postbooster SP rates
(≥10 mIU/mL) in both groups at this time point, which
suggests that the difference in GMC is unlikely to be of
clinical significance. To further investigate the postbooster
anti-HB response, a post hoc analysis was performed for
those participants in group 1 with an anti-HB prebooster
seroprotection rate <10 mIU/mL compared to those with
a prebooster seroprotection rate of ≥10 mIU/mL; while
descriptive and exploratory, and performed using only a
small sample size, this analysis shows that—based on the
10 mIU/mL threshold—the postbooster response is strong
(≥95.0%) irrespective of whether the prebooster antiHB seroprotection rate was above or below 10 mIU/mL.
These data echo those from another study of the DTaPIPV-HB-PRP-T vaccine administered in a 6, 10, 14 week
primary series schedule and including a comparison to
a standalone HB vaccine (14). This adds further support
to that hypothesis that if adequately primed then T and

B cell memory would be expected even in the event of
antibody waning to subprotective levels (21,22), meaning
that a strong and adequate response would be expected
even in such individuals when exposed to wild-type virus.
The WHO also supports this hypothesis, stating ‘the loss
of detectable anti-HBs in participants who had responded
to satisfactorily to a primary series does not necessarily
indicate a lack of protection’ (23,24).
The safety profile was good for both the primary
vaccination series (DTaP-IPV-HB-PRP-T or control
vaccines) and the DTaP-IPV-HB-PRP-T booster (in both
groups) and there were no clinically important differences
between groups. This is as would be expected based on
the extensive experience with the DTaP-IPV-HB-PRP-T
vaccine: despite the possibility for cultural differences
in AE reporting using diary cards (e.g., the anal route
for temperature measurement is not always acceptable
to parents), all clinical studies of DTaP-IPV-HB-PRP-T,
conducted over four continents, have consistently shown
no clinically important safety findings (5).
To conclude, the new hexavalent DTaP-IPV-HBPRP-T vaccine was shown to be immunogenic and safe
as a 2, 3, 4 month primary series without HB vaccination
at birth, comparable to Pentaxim + Engerix B, and a
DTaP-IPV-HB-PRP-T booster was shown to be safe and
immunogenic following a primary series of either DTaPIPV-HB-PRP-T or Pentaxim + Engerix B.
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